Accessibility Menu
Bionano Genomics Stock Quote

Bionano Genomics (NASDAQ: BNGO)

$1.90
(-0.2%)
-0.00
Price as of October 22, 2025, 12:53 p.m. ET

KEY DATA POINTS

Current Price
$1.9
Daily Change
(-0.2%) $0.00
Day's Range
$1.85 - $1.92
Previous Close
$1.9
Open
$1.89
Beta
1.94
Volume
261,822
Average Volume
648,997
Market Cap
18.5M
Market Cap / Employee
$1.90M
52wk Range
$1.5 - $22.8
Revenue
-
Gross Margin
0.05%
Dividend Yield
N/A
EPS
-$44.85
CAPs Rating
-
Industry
Life Sciences Tools and Services

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Bionano Genomics Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
BNGO-90.12%-99.42%-64.27%-100%
S&P+15.06%+95.03%+14.29%+130%

Bionano Genomics Company Info

Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$6.73M-13.4%
Gross Profit$3.48M34.5%
Gross Margin51.64%18.4%
Market Cap$11.03M-71.7%
Market Cap / Employee$0.11M0.0%
Employees100-70.9%
Net Income-$6.86M57.7%
EBITDA-$5.47M68.3%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$3.56M-83.4%
Accounts Receivable$3.49M-44.2%
Inventory8.6-55.7%

Liabilities

Q2 2025YOY Change
Long Term Debt$6.22M7.0%
Short Term Debt$13.36M-38.6%

Ratios

Q2 2025YOY Change
Return On Assets-72.39%29.5%
Return On Invested Capital-132.79%107.7%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$3.49M84.5%
Operating Free Cash Flow-$3.49M84.4%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book0.820.910.150.21-55.21%
Price to Sales1.171.050.260.41-67.15%
Price to Tangible Book Value38.3140.470.200.26-99.44%
Enterprise Value to EBITDA-1.69-4.850.55-0.63-75.14%
Return on Equity-161.8%-170.3%-127.8%-118.3%-14.51%
Total Debt$22.45M$27.30M$18.42M$19.58M-28.98%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.